1 Introduction Prostate cancer (PCa) is the second most common cancer type in men in the Western world (1). The development of castration-resistant prostate cancer (CRPC) and the formation of metastatic disease represent major clinical unmet needs in the treatment of PCa. The current treatment for CRPC includes the use of the cytotoxic agent docetaxel. Docetaxel belongs to the taxane class and binds to the microtubules.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Van
Contact Van, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack